Arvinas’ (ARVN) “Buy” Rating Reaffirmed at Guggenheim

Arvinas (NASDAQ:ARVN)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They presently have a $57.00 target price on the stock. Guggenheim’s price target points to a potential upside of 201.27% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Stifel Nicolaus cut their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a research note on Tuesday. Finally, BMO Capital Markets lowered their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Arvinas presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.67.

Arvinas Trading Up 7.0 %

NASDAQ:ARVN traded up $1.24 during trading hours on Wednesday, reaching $18.92. 292,510 shares of the company traded hands, compared to its average volume of 867,256. The stock has a market capitalization of $1.30 billion, a P/E ratio of -4.05 and a beta of 1.88. The business’s 50-day moving average price is $19.33 and its two-hundred day moving average price is $23.36. Arvinas has a 1 year low of $16.61 and a 1 year high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. During the same period in the previous year, the firm posted ($2.53) earnings per share. As a group, equities analysts anticipate that Arvinas will post -3.22 EPS for the current year.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently modified their holdings of ARVN. Norges Bank purchased a new stake in Arvinas during the 4th quarter worth approximately $23,845,000. BIT Capital GmbH boosted its holdings in Arvinas by 291.7% in the fourth quarter. BIT Capital GmbH now owns 263,527 shares of the company’s stock valued at $5,052,000 after purchasing an additional 196,246 shares during the period. Vanguard Group Inc. raised its position in Arvinas by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock valued at $135,389,000 after purchasing an additional 56,561 shares in the last quarter. LPL Financial LLC grew its position in shares of Arvinas by 12.5% during the fourth quarter. LPL Financial LLC now owns 18,669 shares of the company’s stock worth $358,000 after buying an additional 2,077 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Arvinas during the fourth quarter worth approximately $171,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.